Table 4.
Prevalence of cardiometabolic-related diagnoses
| TGDY vs controls | TGDY prescribed GAHT compared to TGDY not prescribed GAHT | |||||||
|---|---|---|---|---|---|---|---|---|
| TGDY cases No. (%) | Control No. (%) | No GnRHa No. (%) | GnRHa No. (%) | No T No. (%) | T No. (%) | No E2 No. (%) | E2 No. (%) | |
| Overweight/obese | 1764 (42.3) | 5263 (32.0) | 1661 (42.5) | 103 (38.6) | 1273 (39.4) | 491 (52.3) | 1558 (42.1) | 206 (43.5) |
| Dyslipidemia | 351 (8.4) | 806 (4.9) | 340 (8.7) | 11 (4.1) | 218 (6.7) | 133 (14.2) | 298 (8.1) | 53 (11.2) |
| Liver dysfunction | 460 (11.0) | 1360 (8.3) | 434 (11.1) | 26 (9.7) | 326 (10.1) | 134 (14.3) | 389 (10.5) | 71 (15.0) |
| Dysglycemia | 90 (2.2) | 375 (2.3) | 85 (2.2) | 5 (1.9) | 72 (2.2) | 18 (1.9) | 77 (2.1) | 13 (2.7) |
| Hypertension | 373 (8.9) | 1214 (7.4) | 351 (9.0) | 22 (8.2) | 268 (8.3) | 105 (11.2) | 304 (8.2) | 69 (14.6) |
| PCOS | 42 (1.5) | 96 (0.9) | 42 (1.1) | 0 (0) | 33 (1.0) | 9 (1.0) | 39 (1.1) | 3 (0.6) |
Abbreviations: E2, estradiol; GAHT, gender-affirming hormone therapy; GnRHa: gonadotropin-releasing hormone agonist; PCOS, polycystic ovary syndrome; T, testosterone; TGDY, transgender and gender-diverse youth.